30J Stock Overview
A synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IDEAYA Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.20 |
| 52 Week High | US$44.40 |
| 52 Week Low | US$24.00 |
| Beta | 0.86 |
| 11 Month Change | -9.35% |
| 3 Month Change | -26.32% |
| 1 Year Change | -11.27% |
| 33 Year Change | 18.87% |
| 5 Year Change | 273.33% |
| Change since IPO | 309.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 30J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.7% | 0.8% | -1.3% |
| 1Y | -11.3% | -17.5% | 7.4% |
Return vs Industry: 30J exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 30J underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 30J volatility | |
|---|---|
| 30J Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 30J has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 30J's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 124 | Yujiro Hata | www.ideayabio.com |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
IDEAYA Biosciences, Inc. Fundamentals Summary
| 30J fundamental statistics | |
|---|---|
| Market cap | €2.21b |
| Earnings (TTM) | -€171.05m |
| Revenue (TTM) | €3.77m |
590.4x
P/S Ratio-13.0x
P/E RatioIs 30J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 30J income statement (TTM) | |
|---|---|
| Revenue | US$3.92m |
| Cost of Revenue | US$193.26m |
| Gross Profit | -US$189.34m |
| Other Expenses | -US$11.22m |
| Earnings | -US$178.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | -4,827.59% |
| Net Profit Margin | -4,541.56% |
| Debt/Equity Ratio | 0% |
How did 30J perform over the long term?
See historical performance and comparison